152 related articles for article (PubMed ID: 24846624)
1. Bevacizumab treatment for choroidal neovascularization associated with adult-onset foveomacular vitelliform dystrophy.
Tiosano L; Jaouni T; Averbukh E; Grunin M; Banin E; Chowers I
Eur J Ophthalmol; 2014; 24(6):890-6. PubMed ID: 24846624
[TBL] [Abstract][Full Text] [Related]
2. Ranibizumab for choroidal neovascularization associated with adult-onset foveomacular vitelliform dystrophy: one-year results.
Mimoun G; Caillaux V; Querques G; Rothschild PR; Puche N; Souied EH
Retina; 2013 Mar; 33(3):513-21. PubMed ID: 23400081
[TBL] [Abstract][Full Text] [Related]
3. Autosomal recessive best vitelliform macular dystrophy: report of a family and management of early-onset neovascular complications.
Iannaccone A; Kerr NC; Kinnick TR; Calzada JI; Stone EM
Arch Ophthalmol; 2011 Feb; 129(2):211-7. PubMed ID: 21320969
[TBL] [Abstract][Full Text] [Related]
4. Prognosti implications of pigment epithelial detachment in bevacizumab (avastin)-treated eyes with age-related macular degeneration and choroidal neovascularization.
Freeman WR; Kozak I; Yuson RM; Nigam N; Cheng L; Mojana F
Retina; 2011 Oct; 31(9):1812-8. PubMed ID: 21866073
[TBL] [Abstract][Full Text] [Related]
5. Optical Coherence Tomography Angiography of a Choroidal Neovascularization in Adult Onset Foveomacular Vitelliform Dystrophy: Pearls and Pitfalls.
Lupidi M; Coscas G; Cagini C; Coscas F
Invest Ophthalmol Vis Sci; 2015 Dec; 56(13):7638-45. PubMed ID: 26624495
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
Retina; 2007; 27(4):432-8. PubMed ID: 17420694
[TBL] [Abstract][Full Text] [Related]
7. Comparison of macular choroidal thickness in adult onset foveomacular vitelliform dystrophy and age-related macular degeneration.
Coscas F; Puche N; Coscas G; Srour M; Français C; Glacet-Bernard A; Querques G; Souied EH
Invest Ophthalmol Vis Sci; 2014 Jan; 55(1):64-9. PubMed ID: 24282233
[TBL] [Abstract][Full Text] [Related]
8. Functional and anatomic changes in bilateral choroidal neovascularization associated with vitelliform macular dystrophy after intravitreal bevacizumab.
Cennamo G; Cesarano I; Vecchio EC; Reibaldi M; de Crecchio G
J Ocul Pharmacol Ther; 2012 Dec; 28(6):643-6. PubMed ID: 22742532
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors of eyes with naïve subfoveal myopic choroidal neovascularization after intravitreal bevacizumab.
Yang HS; Kim JG; Kim JT; Joe SG
Am J Ophthalmol; 2013 Dec; 156(6):1201-1210.e2. PubMed ID: 24075429
[TBL] [Abstract][Full Text] [Related]
10. Primary intravitreal ranibizumab for adult-onset foveomacular vitelliform dystrophy.
Gallego-Pinazo R; Dolz-Marco R; Pardo-López D; Arevalo JF; Díaz-Llopis M
Graefes Arch Clin Exp Ophthalmol; 2011 Mar; 249(3):455-8. PubMed ID: 20931215
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal ranibizumab for type 3 choroidal neovascularization complicating adult onset foveomacular vitelliform dystrophy.
Querques G; Querques L; Leveziel N; Bandello F; Souied EH
J Fr Ophtalmol; 2013 Jan; 36(1):e1-4. PubMed ID: 23218864
[TBL] [Abstract][Full Text] [Related]
12. Choroidal neovascularization associated with butterfly-shaped pattern dystrophy - a case report.
Świerczyńska M; Danikiewicz-Zagała M; Sedlak L; Nowak-Wąs M; Wyględowska-Promieńska D
Rom J Ophthalmol; 2023; 67(2):185-190. PubMed ID: 37522013
[TBL] [Abstract][Full Text] [Related]
13. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
[TBL] [Abstract][Full Text] [Related]
14. Systemic beta-blockers may reduce the need for repeated intravitreal injections in patients with wet age-related macular degeneration treated by bevacizumab.
Montero JA; Ruiz-Moreno JM; Sanchis-Merino E; Perez-Martin S
Retina; 2013 Mar; 33(3):508-12. PubMed ID: 23099497
[TBL] [Abstract][Full Text] [Related]
15. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS
Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal bevacizumab for choroidal neovascularization secondary to Best vitelliform macular dystrophy in a 6-year-old child.
Chhablani J; Jalali S
Eur J Ophthalmol; 2012; 22(4):677-9. PubMed ID: 22139615
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal triamcinolone, bevacizumab and pegaptanib for occult choroidal neovascularization.
Forte R; Cennamo G; Finelli M; Cesarano I; D'Amico G; De Crecchio G; Cennamo G
Acta Ophthalmol; 2010 Dec; 88(8):e305-10. PubMed ID: 20946332
[TBL] [Abstract][Full Text] [Related]
18. Ranibizumab treatment for choroidal neovascularization secondary to causes other than age-related macular degeneration with good baseline visual acuity.
Erol MK; Ozdemir O; Coban DT; Ceran BB; Bulut M
Semin Ophthalmol; 2014 Mar; 29(2):108-13. PubMed ID: 24409939
[TBL] [Abstract][Full Text] [Related]
19. Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials.
Sharma S; Toth CA; Daniel E; Grunwald JE; Maguire MG; Ying GS; Huang J; Martin DF; Jaffe GJ;
Ophthalmology; 2016 Apr; 123(4):865-75. PubMed ID: 26783095
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series.
Iacono P; Parodi MB; Papayannis A; Kontadakis S; Sheth S; Bandello F
Retina; 2011 Oct; 31(9):1841-7. PubMed ID: 21775926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
